liver tranplantation, partial hepatectomy, pancreatectomy, cirrhosis, anticoagulation, procoagulants
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: - Liver transplantation, right / extended right hepatectomy or pancreatectomy at Kings College Hospital. - >18 years - Signed informed consent Inclusion criteria control group: - >18 years - Signed informed consent
Exclusion criteria
Exclusion criteria: Exclusion criteria study group: - Acute liver failure - Transplantation for non-cirrhotic liver disease - Documented history of hereditary thrombophilia - Use of vitamin K antagonists - Transfusion of blood products (<7 days) - Deep vein thrombosis (<30 days) - HIV positivity Exclusion criteria control group: - Documented history of hereditary thrombophilia - Use of vitamin K antagonists - Transfusion of blood products (<7 days) - History of deep vein thrombosis - Any known form of liver disease - HIV positivity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point of our study is the difference in change of the various parameters of the thrombin generation curve after in vitro addition of a fixed dose of a pro- or anticoagulant drug between patient and control samples. This degree of change indicates the pro- or anticoagulant efficacy of a certain drug as described previously. (Potze W, et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. (PLoS One 2014 Feb 4;9(2):e88390) | — |
Secondary
| Measure | Time frame |
|---|---|
| We do not have any secondary outcome measures, but will assess several other laboratory parameters which we will use to describe the cohort such as the individual coagulation factors, PT, INR, APTT, Fibrinogen, Platelet count and Hb. Indicators of liver function such as GGT, ALT, AST, NH3, alpha1 antitrypsin and ceruloplasmin. | — |
Contacts
Hanzeplein 1